Le Rézo

'en:injection, zoledronic acid (zometa), 1 mg administered'
(id=8088081 ; fe=en:injection, zoledronic acid (zometa), 1 mg administered ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=12416 creation date=2017-07-21 touchdate=2024-09-20 01:19:17.000)

≈ 441 relations sortantes

en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:aneurysm minor diameter <= 6 cm for men
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:capsaicin 8% patch, per 10 square centimeters
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:injection, testosterone enanthate, up to 200 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:ldl-c result not present or not within 12 months prior
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:patient treated for writing but not scored on the writing functional communication measure either at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:score on the attention functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 43 / 1 -> en:score on the spoken language comprehension functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 42 / 0.977 -> en:gene expression profiling panel for use in the management of breast cancer treatment
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 42 / 0.977 -> en:most recent blood pressure not under control, results documented and reviewed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 42 / 0.977 -> en:most recent office visit systolic blood pressure <130 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 42 / 0.977 -> en:prednisone, oral, per 5 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 41 / 0.953 -> en:fetal aneuploidy (trisomy 21, and 18) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 41 / 0.953 -> en:grafix core, per square centimeter
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 41 / 0.953 -> en:most current ldl-c >=100mg/dl
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 40 / 0.93 -> en:aneurysm minor diameter <= 5.5 cm for women
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 40 / 0.93 -> en:implanted pleural catheter, each
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 40 / 0.93 -> en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 39 / 0.907 -> en:anti-lipid treatment contraindicated
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 39 / 0.907 -> en:antiplatelet medication contraindicated
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 39 / 0.907 -> en:assessment of depression severity not documented, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 39 / 0.907 -> en:beta-blocker at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 39 / 0.907 -> en:complete mlh1 and msh2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 39 / 0.907 -> en:injection, brentuximab vedotin, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 38 / 0.884 -> en:anoscopy; with directed submucosal injection(s), any substance
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 38 / 0.884 -> en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 38 / 0.884 -> en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 38 / 0.884 -> en:injection, obinutuzumab, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 38 / 0.884 -> en:miscellaneous supply or accessory for use with ventricular assist device
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 38 / 0.884 -> en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 37 / 0.86 -> en:aneurysm minor diameter >6cm for men
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:5% dextrose in lactated ringer's, 1000 ml
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:adenoma(s) or other neoplasm detected during screening colonoscopy
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:all quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:aneurysm minor diameter <= 5.5 cm
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:anticoagulation was not ordered, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:complete gene sequence analysis; msh2 gene
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:compounded drug, not otherwise classified
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:everolimus, oral, 0.25 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:genetic testing for canavan disease
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:hemodialysis treatment performed less than three times per week or greater than three times per week
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:i intend to report the hypertension (htn) measures group
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:influenza a (h1n1) immunization administration (includes the physician counseling the patient/family)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, alemtuzumab, 10 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, certolizumab pegol, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, factor viii, fc fusion protein, (recombinant), per i.u.
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, ferric carboxymaltose, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, peramivir, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, propofol, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, tbo-filgrastim, 5 micrograms
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:injection, ziv-aflibercept, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:male patients with aneurysms minor diameter >6 cm
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:most recent diastolic blood pressure < 80 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:most recent hemoglobin (hgb) level > 12.0 g/dl
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:most recent office visit systolic blood pressure >=140 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:most recent systolic blood pressure < 130 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:no antiplatelet medication at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:patient documentation - angina assessed as absent
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:patient not treated for motor speech disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:patient treated for spoken language comprehension but not scored on the spoken language comprehension functional communication measure either at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:patient with left ventricular ejection fraction (lvef) >=40% or documentation as normal or mildly depressed left ventricular systolic function
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:score on the attention functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:smoking status and exposure to second hand smoke in the home not assessed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:suicide risk not assessed at the initial evaluation, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 36 / 0.837 -> en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:aneurysm minor diameter >6cm for women
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:assessment of depression severity at the initial evaluation
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incisio
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u.
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:i intend to report the cardiovascular prevention measures group
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:injection, belatacept, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:injection, interferon beta-1a, 11 mcg for subcutaneous use
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:injection, isavuconazonium sulfate, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:injection, paclitaxel, 30 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:injection, testosterone cypionate and estradiol cypionate, up to 1 ml
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:injection, testosterone cypionate, up to 100 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:injection, zoledronic acid (reclast), 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:ldl-c not performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:left ventricular ejection fraction (lvef) was not performed or documented
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:most recent office visit diastolic blood pressure, 80 - 89 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:most recent systolic blood pressure >= 140 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:netupitant 300 mg and palonosetron 0.5 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:no beta-blocker at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:patient documentation - angina assessed as present
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:patient documentation - most recent ldl-c < 100 mg/dl
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:patient had a medical visit in the last 6 months
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:patient not treated for attention disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:patient not treated for reading disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:prescription(s) generated and transmitted via a qualified erx system
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:skin substitute, endoform dermal template, per square centimeter
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 35 / 0.814 -> en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:adenoma(s) or other neoplasm not detected during screening colonoscopy
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:anticoagulation ordered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:clinician documented that patient with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic function was not an eligible candidate for angiotensin converting enzyme (ace) inhibi
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:complete gene sequence analysis for cystic fibrosis genetic testing
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:counseling for diet and physical activity not performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:diabetes screening test not performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:diabetes screening test performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:dna analysis of the f5 gene for susceptibility to factor v leiden thrombophilia
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:i intend to report the back pain measures group
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, blinatumomab, 1 mcg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, ibuprofen, 100 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, medroxyprogesterone acetate for contraceptive use, 150 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, morphine sulfate, 100mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, pembrolizumab, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, testosterone enanthate, up to 100 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:injection, testosterone suspension, up to 50 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:kras mutation analysis
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:most recent office visit diastolic blood pressure >=90 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:most recent systolic blood pressure < 140 mmhg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:most recent systolic blood pressure >= 140 mmhg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:no anti-lipid treatment at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:patient encounter was documented using a pqri qualified ehr or other acceptable systems
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:patient treated for attention but not scored on the attention functional communication measure either at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:severity of angina assessed according to level of activity
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:spinal orthosis, anterior-posterior-lateral control, with interface material, custom fitted (dewall posture protector only)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:urine protein test was not performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 34 / 0.791 -> en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:ankle orthosis, ankle gauntlet or similar, with or without joints, a prefabricated, off-the-shelf
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:anti-lipid treatment at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:anticoagulation not ordered for reasons documented by clinician
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:antiplatelet medication at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:cd4+ cell count or percentage not documented as performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:circulating tumor cell test
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:counseling for diet and physical activity performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:dna analysis, fecal, for colorectal cancer screening
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure 60 minutes or longer, as documented in the anesthesia record
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:electronic wrist rotator, for utah arm
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:eligible professional does not have prescribing privileges
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:factor ix (antihemophilic factor, recombinant), alprolix, per i.u.
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:fluocinolone acetonide, intravitreal implant
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:genetic testing for gaucher disease
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:grafix prime, per square centimeter
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:i intend to report the community-acquired pneumonia (cap) measures group
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:injection, epoetin beta, 1 microgram, (for esrd on dialysis)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:injection, immune globulin (bivigam), 500 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:injection, omacetaxine mepesuccinate, 0.01 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:injection, pasireotide long acting, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:injection, peginesatide, 0.1 mg (for esrd on dialysis)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:injection, testosterone enanthate and estradiol valerate, up to 1 cc administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:ldl-c was not performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:other symptomatic patient with ipsilateral carotid territory tia or stroke > 120 days prior to cea, or contralateral carotid territory tia or stroke or vertebrobasilar tia or stroke
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:patient did not have a medical visit in the last 6 months
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:patient did not have the retina attached after 6 months following only one surgery
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:patient not treated for writing disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:patient treated for motor speech but not scored on the motor speech comprehension functional communication measure either at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:rehabilitation services (occupational, physical or speech) ordered at or prior to discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:rehabilitation services were not ordered, reason not otherwise specified
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:score on the motor speech functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:score on the spoken language expression functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:suicide risk assessed at the initial evaluation
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 32 / 0.744 -> en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:ankle orthosis, ankle gauntlet or similar, with or without joints, custom a fabricated
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:clinician documented that patient did not receive conventional cea
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:clinician documented that patient is not an eligible candidate for counseling regarding contraception prior to antiviral treatment; patient not receiving antiviral treatment for hepatitis c
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:complete gene sequence analysis; brca1 gene
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:documentation of patient reason(s) for patient not receiving counseling for diet and physical activity (e.g., patient is not willing to discuss diet or exercise interventions to help control blood pressure, or the patient said he/she refused to make th
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:electronic wrist rotator, otto bock or equal
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:epifix, per square centimeter
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:female patients with aneurysm minor diameter 5.6-6.0 cm
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:follow-up cta, duplex, or mra of the abdomen and pelvis performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:hemodialysis treatment performed exactly three times per week for > 90 days
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:hydroxyzine pamoate, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:ileoscopy,through stoma; with transendoscopic stent placement (includes predilation)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, ado-trastuzumab emtansine, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, aflibercept, 1 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, alemtuzumab, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, factor viii fc fusion protein(recombinant), per iu
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, interferon beta-1a, 11 mcg for intramuscular use
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, medroxyprogesterone acetate, 50 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, morphine sulfate (preservative-free sterile solution), per 10 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, oritavancin, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, siltuximab, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, tedizolid phosphate, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, testosterone propionate, up to 100 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:injection, vedolizumab, 1 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:levonorgestrel 52mg intrauterine system
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:levonorgestrel-releasing intrauterine contraceptive system, (skyla), 13.5 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:lvf testing documented as being performed prior to discharge or in the previous 12 months
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:maternal serum triple marker screen including alpha-fetoprotein (afp), estriol, and human chorionic gonadotropin (hcg)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:most recent blood pressure under control
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:most recent ldl-c not under control, results documented and reviewed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:most recent ldl-c under control, results documented and reviewed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:most recent office visit systolic blood pressure, 130 to 139 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:no documentation of blood pressure measurement, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:patch closure used for patient undergoing conventional cea
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:patient not treated for spoken language expression disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:patient receiving antiviral treatment for hepatitis c documented
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:pregnancy test (urine or serum) ordered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:severity of angina not assessed according to level of activity
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:total kt/v greater than or equal to 1.7 per week (total clearance of urea [kt] / volume [v])
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:type, anatomic location, and activity all documented
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 31 / 0.721 -> en:vacuum drainage bottle and tubing for use with implanted catheter
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:all quality actions for the applicable measures in the back pain measures group have been performed for this patient
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:aneurysm minor diameter <= 5.5 cm for men
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:aneurysm minor diameter 5.6-6.0 cm
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:aneurysm minor diameter 5.6-6.0 cm for women
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:beta blocker contraindicated
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:complete gene sequence analysis for hemochromatosis genetic testing
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:genetic testing for tay-sachs disease
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:hcpcs level ii preferred terms, obsolete
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:injection, ferric pyrophosphate citrate solution, 0.1 mg of iron
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:injection, sculptra, 0.1 ml
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:intraoperative radiation therapy (single administration)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:ldl value < 100
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:level of activity and symptoms not assessed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:mandibular orthopedic repositioning device, each
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:most current ldl-c <100mg/dl
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:most recent diastolic blood pressure >= 90 mmhg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:most recent hemoglobin level <= 12.0 g/dl
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:patch closure not used for patient undergoing conventional cea, reason not specified
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:patient is not eligible for the referral for otologic evaluation measure
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:patient not treated for memory disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:patient receiving hemodialysis, peritoneal dialysis or kidney transplantation
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:percutaneous vertebroplasty, one vertebral body, unilateral or bilateral injection; cervical
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:perphenazine, 8mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:pregnancy test (urine or serum) was not ordered, reason not specified
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:score on the memory functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:serum creatinine test not performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:tissue marker (implantable)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 30 / 0.698 -> en:urine protein test result documented and reviewed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:12-lead electrocardiogram (ecg) performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:all quality actions for the applicable measures in the community-acquired pneumonia (cap) measures group have been performed for this patient
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:asymptomatic patient with no history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:clinician documented that patient is receiving antiviral treatment for hepatitis c
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:complete gene sequence analysis; mlh1 gene
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:documentation of diagnosis of chronic kidney disease
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:documentation of medical reason(s) for not performing serum creatinine test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:documentation of medical reason(s) for not prescribing oral aspirin or other antthrombotic therapy (e.g., patient documented to be low risk or patient with terminal illness or treatment of hypertension with standard treatment goals is not clinically ap
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:documentation of medical reason(s) for patient not receiving counseling for diet and physical activity (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:each additional cervical vertebral body (list separately in addition to code for primary procedure)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:fetal aneuploidy (trisomy 21, 18, and 13) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:hemoglobin level measurement not documented, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:i intend to report the epilepsy measures group
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:injectin, epoetin beta, 1 microgram, (for non esrd use)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:injection, aflibercept, 2 mg vial
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:injection, belinostat, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:injection, ceftolozane 50 mg and tazobactam 25 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:injection, elosulfase alfa, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:injection, ocriplasmin, 0.125 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:injection, sulfur hexafluoride lipid microsphere, per ml
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:lipid profile not performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:most recent diastolic blood pressure >= 90 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:most recent diastolic blood pressure 80 - 89 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:most recent systolic blood pressure 130 to 139 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:negative pressure ventilator; portable or stationary
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:patient did not achieve flat retinas six months post surgery
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:patient is not eligible for follow-up cta, duplex, or mra (e.g., patient death, failure to return for scheduled follow-up exam, planned follow-up study which will meet numerator criteria has not yet occurred at the time of reporting)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:patient not treated for spoken language comprehension disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:patients with a positive hepatitis c antibody test
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:score on the reading functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:score on the spoken language expression functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 29 / 0.674 -> en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:all quality actions for the applicable measures in the perioperative care measures group have been performed for this patient
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:assessed level of activity and symptoms
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:autogenous av fistula received
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:blood pressure measurement not documented, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:cd4+ cell count or cd4+ cell percentage results documented
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:chlorpromazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:clinician documented that patient was not an eligible candidate for autogenous av fistula
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:dronabinol, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:genetic testing for detection of mutations in the presenilin - 1 gene
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:injection, human fibrinogen concentrate, 1 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:injection, human fibrinogen concentrate, 100 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:injection, pertuzumab, 10 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:injection, taliglucerase alfa, 10 units
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:injection, testosterone undecanoate, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:injection, zoledronic acid, not otherwise specified, 1mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:ldl value >= 100
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:linear accelerator based stereotactic radiosurgery, complete course of therapy in one session
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:most recent diastolic blood pressure < 90 mmhg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:most recent ldl-c >= 100 mg/dl
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:no documentation of disease type, anatomic location, and activity, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:oral aspirin or other antithrombotic therapy prescribed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:promethazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:spirometry test results demonstrate fev1 >= 60% predicted or patient does not have copd symptoms
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:the eligible professional practices in an area without sufficient available pharmacies for electronic prescribing and requests a hardship exemption for the application of the payment adjustment under section 1848(a)(5)(a) of the social security act
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 28 / 0.651 -> en:unlisted procedure, intestine
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:12-lead electrocardiogram (ecg) not performed, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:abdominal aortic aneurysm is not infarenal
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:aneurysm minor diameter 5.6-6.0 cm for men
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed for patients with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic fun
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:automated eeg monitoring
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:complete and appropriate patient data were reported to a qualified clinical database registry
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:complete gene sequence analysis; brca2 gene
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:dicom format image data availability not documented in final report due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:documentation of medical reason(s) for not performing lipid profile (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:documentation of medical reason(s) for not performing urine protein test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not cllinically appropriate)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:female patients with aneurysm minor diameter >6cm
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:i intend to report the ischemic vascular disease (ivd) measures group
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:i intend to report the perioperative care measures group
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:influenza a (h1n1) vaccine, any route of administration
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:injection, carfilzomib, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:injection, dalbavancin, 10 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:injection, filgrastim (g-csf), 300 mcg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:injection, filgrastim (g-csf), 480 mcg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:injection, nivolumab, 1 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:injection, ramucirumab, 5 mg administered
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:injection, testosterone cypionate, 1 cc, 200 mg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:insertion of ocular telescope prosthesis including removal of crystalline lens
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:most recent office visit diastolic blood pressure, <80 mm hg
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:patient not receiving a first course of anti-tnf therapy
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:patient not treated for swallowing disorder
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:patient treated for memory but not scored on the memory functional communication measure either at admission or at discharge
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:pneumocystis jiroveci pneumonia prophlaxis prescribed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:positive airway pressure therapy not prescribed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:pregnancy test (urine or serum) not ordered for reasons documented by clinician
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:pressure support ventilator with volume control mode, may include pressure control mode, used with non-invasive interface (e.g., mask)
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:prostate cancer antigen 3 (pca3) testing
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:score on the swallowing functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:score on the writing functional communication measure at discharge was higher than at admission
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:score on the writing functional communication measure at discharge was not higher than at admission, reason not given
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:serum creatinine test result documented and reviewed
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:single-mutation analysis (in individual with a known mlh1 and msh2 mutation in the family) for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v])
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> en:zoledronic acid
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 27 / 0.628 -> injection
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 26 / 0.605 -> acide
en:injection, zoledronic acid (zometa), 1 mg administered -- r_associated #0: 26 / 0.605 -> en:due to medical reasons, search not conducted for dicom format images for prior patient ct imaging studies completed at non-affiliated external heatlhcare facilities or entities within the past 12 months that are available through a secure, authorized

≈ 441 relations entrantes

en:beta-blocker at discharge --- r_associated #0: 43 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete gene sequence analysis; mlh1 gene --- r_associated #0: 42 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain --- r_associated #0: 42 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, factor viii, fc fusion protein, (recombinant), per i.u. --- r_associated #0: 42 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, sculptra, 0.1 ml --- r_associated #0: 42 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery --- r_associated #0: 42 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb) --- r_associated #0: 42 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device --- r_associated #0: 41 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:urine protein test was not performed, reason not given --- r_associated #0: 41 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:miscellaneous supply or accessory for use with ventricular assist device --- r_associated #0: 40 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, peginesatide, 0.1 mg (for esrd on dialysis) --- r_associated #0: 39 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the attention functional communication measure at discharge was higher than at admission --- r_associated #0: 37 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:compounded drug, not otherwise classified --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:i intend to report the hypertension (htn) measures group --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, alemtuzumab, 10 mg administered --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, belinostat, 10 mg --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone enanthate, up to 200 mg administered --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent blood pressure under control --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:no anti-lipid treatment at discharge --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient receiving antiviral treatment for hepatitis c documented --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pregnancy test (urine or serum) not ordered for reasons documented by clinician --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube) --- r_associated #0: 36 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required) --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u. --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, morphine sulfate, 100mg --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, taliglucerase alfa, 10 units --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ziv-aflibercept, 1 mg --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:level of activity and symptoms not assessed --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for attention disorder --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pregnancy test (urine or serum) was not ordered, reason not specified --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:promethazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask) --- r_associated #0: 35 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:abdominal aortic aneurysm is not infarenal --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:diabetes screening test not performed, reason not given --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u. --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:hcpcs level ii preferred terms, obsolete --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:i intend to report the perioperative care measures group --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok) --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ferric carboxymaltose, 1 mg --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, medroxyprogesterone acetate, 50 mg --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, pertuzumab, 10 mg --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c) --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:no documentation of disease type, anatomic location, and activity, reason not given --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:positive airway pressure therapy not prescribed --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:prednisone, oral, per 5 mg --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the swallowing functional communication measure at discharge was higher than at admission --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:severity of angina assessed according to level of activity --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel --- r_associated #0: 34 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation) --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of diagnosis of chronic kidney disease --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:dronabinol, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:fluocinolone acetonide, intravitreal implant --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:i intend to report the community-acquired pneumonia (cap) measures group --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ocriplasmin, 0.125 mg --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent ldl-c under control, results documented and reviewed --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient documentation - angina assessed as present --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for memory disorder --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for spoken language expression disorder --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the motor speech functional communication measure at discharge was higher than at admission --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v]) --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v]) --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given --- r_associated #0: 32 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.) --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, sulfur hexafluoride lipid microsphere, per ml --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band) --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ldl-c not performed, reason not given --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent office visit diastolic blood pressure, 80 - 89 mm hg --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:rehabilitation services were not ordered, reason not otherwise specified --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the writing functional communication measure at discharge was higher than at admission --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:the eligible professional practices in an area without sufficient available pharmacies for electronic prescribing and requests a hardship exemption for the application of the payment adjustment under section 1848(a)(5)(a) of the social security act --- r_associated #0: 31 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter 5.6-6.0 cm for women --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:antiplatelet medication contraindicated --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient is not an eligible candidate for counseling regarding contraception prior to antiviral treatment; patient not receiving antiviral treatment for hepatitis c --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete gene sequence analysis; brca1 gene --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete gene sequence analysis; brca2 gene --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:counseling for diet and physical activity performed --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not performing serum creatinine test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not performing urine protein test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not cllinically appropriate) --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure 60 minutes or longer, as documented in the anesthesia record --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:grafix core, per square centimeter --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:i intend to report the back pain measures group --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:i intend to report the epilepsy measures group --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:influenza a (h1n1) vaccine, any route of administration --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ado-trastuzumab emtansine, 1 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ceftolozane 50 mg and tazobactam 25 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, certolizumab pegol, 1 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, isavuconazonium sulfate, 1 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, medroxyprogesterone acetate for contraceptive use, 150 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, oritavancin, 10 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, paclitaxel, 30 mg administered --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, pasireotide long acting, 1 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone undecanoate, 1 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ldl-c result not present or not within 12 months prior --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:left ventricular ejection fraction (lvef) was not performed or documented --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c) --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:maternal serum triple marker screen including alpha-fetoprotein (afp), estriol, and human chorionic gonadotropin (hcg) --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent ldl-c not under control, results documented and reviewed --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent office visit diastolic blood pressure, <80 mm hg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent systolic blood pressure >= 140 mm hg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:netupitant 300 mg and palonosetron 0.5 mg --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:oral aspirin or other antithrombotic therapy prescribed --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patch closure used for patient undergoing conventional cea --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient documentation - angina assessed as absent --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for swallowing disorder --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient receiving hemodialysis, peritoneal dialysis or kidney transplantation --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for spoken language comprehension but not scored on the spoken language comprehension functional communication measure either at admission or at discharge --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:rehabilitation services (occupational, physical or speech) ordered at or prior to discharge --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the reading functional communication measure at discharge was higher than at admission --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:spirometry test results demonstrate fev1 >= 60% predicted or patient does not have copd symptoms --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:vacuum drainage bottle and tubing for use with implanted catheter --- r_associated #0: 30 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:all quality actions for the applicable measures in the back pain measures group have been performed for this patient --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter <= 5.5 cm for men --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anti-lipid treatment at discharge --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:cd4+ cell count or percentage not documented as performed, reason not given --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:dicom format image data availability not documented in final report due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v]) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:electronic wrist rotator, otto bock or equal --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:influenza a (h1n1) immunization administration (includes the physician counseling the patient/family) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, dalbavancin, 10 mg administered --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, epoetin beta, 1 microgram, (for esrd on dialysis) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, filgrastim (g-csf), 480 mcg --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, tedizolid phosphate, 1 mg --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ldl-c was not performed --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:linear accelerator based stereotactic radiosurgery, complete course of therapy in one session --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent hemoglobin level <= 12.0 g/dl --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patients with a positive hepatitis c antibody test --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:prostate cancer antigen 3 (pca3) testing --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:severity of angina not assessed according to level of activity --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:suicide risk assessed at the initial evaluation --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:total kt/v greater than or equal to 1.7 per week (total clearance of urea [kt] / volume [v]) --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:unlisted procedure, intestine --- r_associated #0: 29 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter <= 5.5 cm --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter <= 5.5 cm for women --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anticoagulation not ordered for reasons documented by clinician --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:assessed level of activity and symptoms --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:assessment of depression severity at the initial evaluation --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient is receiving antiviral treatment for hepatitis c --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete and appropriate patient data were reported to a qualified clinical database registry --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:counseling for diet and physical activity not performed, reason not given --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for patient not receiving counseling for diet and physical activity (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:everolimus, oral, 0.25 mg --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:genetic testing for canavan disease --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:grafix prime, per square centimeter --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:hemoglobin level measurement not documented, reason not given --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, human fibrinogen concentrate, 1 mg administered --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, human fibrinogen concentrate, 100 mg --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone cypionate and estradiol cypionate, up to 1 ml --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone cypionate, up to 100 mg --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone enanthate and estradiol valerate, up to 1 cc administered --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:levonorgestrel-releasing intrauterine contraceptive system, (skyla), 13.5 mg --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:no antiplatelet medication at discharge --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient encounter was documented using a pqri qualified ehr or other acceptable systems --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient had a medical visit in the last 6 months --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for reading disorder --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the attention functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the spoken language comprehension functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the spoken language expression functional communication measure at discharge was higher than at admission --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:serum creatinine test not performed, reason not given --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation) --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:suicide risk not assessed at the initial evaluation, reason not given --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens --- r_associated #0: 28 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter <= 6 cm for men --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:autogenous av fistula received --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation) --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete mlh1 and msh2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg) --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:each additional cervical vertebral body (list separately in addition to code for primary procedure) --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:follow-up cta, duplex, or mra of the abdomen and pelvis performed --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:gene expression profiling panel for use in the management of breast cancer treatment --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:genetic testing for gaucher disease --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:implanted pleural catheter, each --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, brentuximab vedotin, 1 mg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, carfilzomib, 1 mg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, interferon beta-1a, 11 mcg for subcutaneous use --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, morphine sulfate (preservative-free sterile solution), per 10 mg administered --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone cypionate, 1 cc, 200 mg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone enanthate, up to 100 mg administered --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone suspension, up to 50 mg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, vedolizumab, 1 mg administered --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ldl value < 100 --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:levonorgestrel 52mg intrauterine system --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:lipid profile not performed, reason not given --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:mandibular orthopedic repositioning device, each --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most current ldl-c <100mg/dl --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent diastolic blood pressure < 80 mm hg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent diastolic blood pressure >= 90 mm hg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent office visit systolic blood pressure <130 mm hg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent systolic blood pressure < 130 mm hg --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:negative pressure ventilator; portable or stationary --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for motor speech disorder --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pneumocystis jiroveci pneumonia prophlaxis prescribed --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:prescription(s) generated and transmitted via a qualified erx system --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the writing functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:serum creatinine test result documented and reviewed --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:zoledronic acid --- r_associated #0: 27 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter >6cm for men --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ankle orthosis, ankle gauntlet or similar, with or without joints, a prefabricated, off-the-shelf --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:asymptomatic patient with no history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:automated eeg monitoring --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:blood pressure measurement not documented, reason not given --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete gene sequence analysis for hemochromatosis genetic testing --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete gene sequence analysis; msh2 gene --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:female patients with aneurysm minor diameter 5.6-6.0 cm --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:fetal aneuploidy (trisomy 21, 18, and 13) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:hemodialysis treatment performed exactly three times per week for > 90 days --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:hemodialysis treatment performed less than three times per week or greater than three times per week --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, aflibercept, 1 mg administered --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, elosulfase alfa, 1 mg --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, peramivir, 1 mg --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, siltuximab, 10 mg --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ldl value >= 100 --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient is not eligible for follow-up cta, duplex, or mra (e.g., patient death, failure to return for scheduled follow-up exam, planned follow-up study which will meet numerator criteria has not yet occurred at the time of reporting) --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pregnancy test (urine or serum) ordered --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique --- r_associated #0: 26 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:all quality actions for the applicable measures in the community-acquired pneumonia (cap) measures group have been performed for this patient --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:all quality actions for the applicable measures in the perioperative care measures group have been performed for this patient --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies) --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anticoagulation was not ordered, reason not given --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete gene sequence analysis for cystic fibrosis genetic testing --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:diabetes screening test performed --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment) --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:genetic testing for detection of mutations in the presenilin - 1 gene --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:i intend to report the ischemic vascular disease (ivd) measures group --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, factor viii fc fusion protein(recombinant), per iu --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, immune globulin (bivigam), 500 mg --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, interferon beta-1a, 11 mcg for intramuscular use --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, omacetaxine mepesuccinate, 0.01 mg --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, zoledronic acid (reclast), 1 mg --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent diastolic blood pressure >= 90 mmhg --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent office visit systolic blood pressure, 130 to 139 mm hg --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patch closure not used for patient undergoing conventional cea, reason not specified --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient did not achieve flat retinas six months post surgery --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient is not eligible for the referral for otologic evaluation measure --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for memory but not scored on the memory functional communication measure either at admission or at discharge --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for motor speech but not scored on the motor speech comprehension functional communication measure either at admission or at discharge --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for writing but not scored on the writing functional communication measure either at admission or at discharge --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:perphenazine, 8mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the memory functional communication measure at discharge was higher than at admission --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:score on the spoken language expression functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:tissue marker (implantable) --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:urine protein test result documented and reviewed --- r_associated #0: 25 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ankle orthosis, ankle gauntlet or similar, with or without joints, custom a fabricated --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anti-lipid treatment contraindicated --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient was not an eligible candidate for autogenous av fistula --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:female patients with aneurysm minor diameter >6cm --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:genetic testing for tay-sachs disease --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injectin, epoetin beta, 1 microgram, (for non esrd use) --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, aflibercept, 2 mg vial --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, alemtuzumab, 1 mg --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, belatacept, 1 mg --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, blinatumomab, 1 mcg --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, obinutuzumab, 10 mg --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most current ldl-c >=100mg/dl --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent diastolic blood pressure 80 - 89 mm hg --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent hemoglobin (hgb) level > 12.0 g/dl --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent office visit diastolic blood pressure >=90 mm hg --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient did not have the retina attached after 6 months following only one surgery --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for spoken language comprehension disorder --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient with left ventricular ejection fraction (lvef) >=40% or documentation as normal or mildly depressed left ventricular systolic function --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:percutaneous vertebroplasty, one vertebral body, unilateral or bilateral injection; cervical --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:smoking status and exposure to second hand smoke in the home not assessed, reason not given --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens --- r_associated #0: 24 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter 5.6-6.0 cm for men --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anoscopy; with directed submucosal injection(s), any substance --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not performing lipid profile (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:electronic wrist rotator, for utah arm --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:factor ix (antihemophilic factor, recombinant), alprolix, per i.u. --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, pembrolizumab, 1 mg --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:insertion of ocular telescope prosthesis including removal of crystalline lens --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:intraoperative radiation therapy (single administration) --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:male patients with aneurysms minor diameter >6 cm --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent systolic blood pressure < 140 mmhg --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:no beta-blocker at discharge --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:other symptomatic patient with ipsilateral carotid territory tia or stroke > 120 days prior to cea, or contralateral carotid territory tia or stroke or vertebrobasilar tia or stroke --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:pressure support ventilator with volume control mode, may include pressure control mode, used with non-invasive interface (e.g., mask) --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:skin substitute, endoform dermal template, per square centimeter --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:spinal orthosis, anterior-posterior-lateral control, with interface material, custom fitted (dewall posture protector only) --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:type, anatomic location, and activity all documented --- r_associated #0: 23 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:12-lead electrocardiogram (ecg) not performed, reason not given --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:12-lead electrocardiogram (ecg) performed --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:all quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter 5.6-6.0 cm --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:anticoagulation ordered --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:chlorpromazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:circulating tumor cell test --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient did not receive conventional cea --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:dna analysis, fecal, for colorectal cancer screening --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:eligible professional does not have prescribing privileges --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:hydroxyzine pamoate, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:hyperbaric oxygen under pressure, full body chamber, per 30 minute interval --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:ileoscopy,through stoma; with transendoscopic stent placement (includes predilation) --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, filgrastim (g-csf), 300 mcg --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ibuprofen, 100 mg --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, propofol, 10 mg --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, tbo-filgrastim, 5 micrograms --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, testosterone propionate, up to 100 mg --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:kras mutation analysis --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:lvf testing documented as being performed prior to discharge or in the previous 12 months --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent blood pressure not under control, results documented and reviewed --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent diastolic blood pressure < 90 mmhg --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent ldl-c >= 100 mg/dl --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent systolic blood pressure 130 to 139 mm hg --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:no documentation of blood pressure measurement, reason not given --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient documentation - most recent ldl-c < 100 mg/dl --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not treated for writing disorder --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient treated for attention but not scored on the attention functional communication measure either at admission or at discharge --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel --- r_associated #0: 22 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:5% dextrose in lactated ringer's, 1000 ml --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:adenoma(s) or other neoplasm detected during screening colonoscopy --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:adenoma(s) or other neoplasm not detected during screening colonoscopy --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:aneurysm minor diameter >6cm for women --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:antiplatelet medication at discharge --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:assessment of depression severity not documented, reason not given --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:beta blocker contraindicated --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:capsaicin 8% patch, per 10 square centimeters --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:cd4+ cell count or cd4+ cell percentage results documented --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:dna analysis of the f5 gene for susceptibility to factor v leiden thrombophilia --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:epifix, per square centimeter --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:fetal aneuploidy (trisomy 21, and 18) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:i intend to report the cardiovascular prevention measures group --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ferric pyrophosphate citrate solution, 0.1 mg of iron --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, nivolumab, 1 mg --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, ramucirumab, 5 mg administered --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:injection, zoledronic acid, not otherwise specified, 1mg --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent office visit systolic blood pressure >=140 mm hg --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:most recent systolic blood pressure >= 140 mmhg --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient did not have a medical visit in the last 6 months --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:patient not receiving a first course of anti-tnf therapy --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:single-mutation analysis (in individual with a known mlh1 and msh2 mutation in the family) for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing --- r_associated #0: 21 --> en:injection, zoledronic acid (zometa), 1 mg administered
acide --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy prescribed for patients with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic fun --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incisio --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:clinician documented that patient with a left ventricular ejection fraction (lvef) <40% or documentation of moderately or severely depressed left ventricular systolic function was not an eligible candidate for angiotensin converting enzyme (ace) inhibi --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of medical reason(s) for not prescribing oral aspirin or other antthrombotic therapy (e.g., patient documented to be low risk or patient with terminal illness or treatment of hypertension with standard treatment goals is not clinically ap --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:documentation of patient reason(s) for patient not receiving counseling for diet and physical activity (e.g., patient is not willing to discuss diet or exercise interventions to help control blood pressure, or the patient said he/she refused to make th --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered
en:due to medical reasons, search not conducted for dicom format images for prior patient ct imaging studies completed at non-affiliated external heatlhcare facilities or entities within the past 12 months that are available through a secure, authorized --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered
injection --- r_associated #0: 20 --> en:injection, zoledronic acid (zometa), 1 mg administered